The double immunostaining of CD133 and ki-67 favours a significant co-localization pattern in fibroblastic subtype of meningiomas;Podwójne znakowanie immunologiczne CD133 i ki-67 wskazuje na ich istotn1 wspó3lokalizacjê w podtypie w3óknistym oponiaków

Neurologia i Neurochirurgia Polska

Volumn 45, Issue 5, 2011, Pages 467-473

  Albayrak, Baki S ^a   Ismailoglu, Ozgur ^a   Tanriover, Gamze ^b   Cetinalp, Eralp N ^c   Demir, Necdet ^b  

^a SULEYMAN DEMIREL UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

^c Etlik Training and Teaching Hospital ^*  (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; KI 67 ANTIGEN;

ARTICLE; CANCER TISSUE; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT MENINGIOMA; MEDULLOBLASTOMA; MENINGIOMA;

EID: 82855175334     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.1016/S0028-3843(14)60315-7     Document Type: Article

References (11)

1. Albayrak B.S., Black P.M. The origin of meningiomas. In: Pamir M.N., Black P.M., Fahlbusch R. (eds.). Meningio - mas: A Comprehensive Text. 1st ed. Saunders, Philadelphia 2010, p. 53.
2. Black P.M. Meningiomas. Neurosurgery 1993; 32: 643-657.
3. Yamashima T. On arachnoid villi and meningiomas: functional implication of ultrastructure, cell adhesion mechanisms, and extracellular matrix composition. Pathol Oncol Res 1996; 2: 144-149.
4. Kleihues P., Louis D.N., Scheithauer B.W., et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-225 [discussion: 226-229].
5. Kalamarides M., Stemmer-Rachamimov A.O., Takahashi M., et al. Natural history of meningioma development in mice reveals a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol 2008; 18: 62-70.
6. Riemenschneider M.J., Perry A., Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol 2006; 5: 1045-1054.
7. Suzuki S.O., Iwaki T., Kitamoto T., et al. Differential expression of CD44 variants among meningioma subtypes. Clin Mol Pathol 1996; 49: 140-146.
8. Rooprai H.K., Liyanage K., King A., et al. CD44 expression in human meningiomas: an immunocytochemical, immunohistochemical and flow cytometric analysis. Int J Oncol 1999; 14: 855-860.
9. Sainio M., Zhao F., Heiska L., et al. Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci 1997; 110: 2249-2260.
10. Kalamarides M., Niwa-Kawakita M., Leblois H., et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Gene Dev 2002; 16: 1060-1065.
11. Singh S.K., Clarke I.D., Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.